Tagista, tablets 8 mg 30 pcs

Tagiste has a histamine-like, microcirculatory improving effect.

Pharmacodynamics

Betahistine acts mainly on the histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

At the direct agonist effect on the H1-receptors of the inner ear vessels and also indirectly through the effect on the RH-receptors it improves microcirculation and capillary permeability and normalizes the endolymph pressure in the labyrinth and cochlea.

At the same time betahistine increases blood flow in the basilar artery. It has a pronounced central effect, being an inhibitor of NZ-receptor nuclei of the vestibular nerve.

Normalizes conduction in neurons of vestibular nuclei at brainstem level. Clinical manifestation of the above properties is reduction of the frequency and intensity of dizziness, decrease of tinnitus, improvement of hearing if it is reduced.

Pharmacokinetics

Absorbed rapidly, binding to plasma proteins is low. Time of reaching maximum concentration in blood plasma – 3 hours.

Extracted almost completely by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours.

The elimination half-life is 3 – 4 hours.

Indications

Treatment and prevention of vestibular vertigo of various origins;
Syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
Meniere’s disease or syndrome.

Pharmacological effect

Tagista has a histamine-like effect that improves microcirculation.

Pharmacodynamics

Betahistine acts primarily on histamine H1 and H3 receptors in the inner ear and vestibular nuclei of the central nervous system.

Through a direct agonistic effect on H1 receptors of the vessels of the inner ear, as well as indirectly through an effect on NZ receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea.

At the same time, betahistine increases blood flow in the basilar artery. It has a pronounced central effect, being an inhibitor of NS receptors in the nuclei of the vestibular nerve.

Normalizes conductivity in the neurons of the vestibular nuclei at the level of the brain stem. The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.

Pharmacokinetics

Absorbed quickly, binding to plasma proteins is low. The time to reach maximum concentration in blood plasma is 3 hours.

Almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours.

The half-life is 3 – 4 hours.

Special instructions

Betahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities requiring rapid psychomotor reactions.

Active ingredient

Betahistine

Composition

1 tablet contains

Active ingredient:

Betahistine dihydrochloride 8.0 mg;

Excipients:

Microcrystalline cellulose – 54.75 mg,

Povidone (kollidon 25) – 9.0 mg

Potato starch – 20.0 mg,

Citric acid – 2.0 mg,

Colloidal silicon dioxide (Aerosil), – 3.0 mg,

Talc – 2.8 mg,

Magnesium stearate – 0.45 mg.

Contraindications

Hypersensitivity to any of the components of the drug;
age under 18 years (due to lack of data);
pregnancy and lactation (due to lack of data).
With caution

Peptic ulcer of the stomach or duodenum (including a history), pheochromocytoma, bronchial asthma.

These patients should be monitored regularly during treatment.

Side Effects

Gastrointestinal disorders,
hypersensitivity reactions on the skin (rash, itching, urticaria),
Quincke’s edema.

Interaction

There are no known cases of interaction or incompatibility with other drugs.

Overdose

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, taking activated carbon, symptomatic therapy.

Prescribing

Histamine drug.

Functional features

Absorbed quickly, binding to plasma proteins is low.

Time to reach maximum concentration in blood plasma – 3 hours

Almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours.

The half-life is 3-4 hours.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life

4 years. Do not use after the expiration date stated on the package.

Manufacturer

Hemofarm LLC, Russia